Days After US Aflibercept Approval, Sandoz Is Hit By Regeneron Lawsuit

 
• By Dave Wallace
  
Eye with reflection of word "legal"
Regeneron said Sandoz has not followed the BPCIA’s “patent dance.” • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics